.svg)
You are now leaving Astellas.us. The website you are linking to is neither owned nor controlled by Astellas.
Astellas is not responsible for the content or services on this site.
News Releases
Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
-
Jul 16, 2019-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology-
Jul 10, 2019Glinski to Oversee US Sales for XTANDI-
Jun 3, 2019-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-
-
May 30, 2019- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] -
-
May 20, 2019-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply -
-
May 5, 2019- Data Presented at the American Urological Association 2019 Annual Meeting -
